Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Discovery and selection of HBV-derived T cell epitopes for global immunotherapy based on viral indispensability, conservation and HLA-binding strength.

de Beijer MTA, Jansen DTSL, Dou Y, van Esch WJE, Mok JY, Maas MJP, Brasser G, de Man RA, Woltman AM, Buschow SI.

J Virol. 2019 Dec 18. pii: JVI.01663-19. doi: 10.1128/JVI.01663-19. [Epub ahead of print]

2.

Elevated serum levels of soluble CD14 in HBeAg-positive chronic HBV patients upon Peginterferon treatment are associated with treatment response.

Dou Y, van Montfoort N, van den Bosch A, Janssen HLA, de Man RA, Buschow SI, Woltman AM.

J Viral Hepat. 2019 Sep;26(9):1076-1085. doi: 10.1111/jvh.13127. Epub 2019 Jun 3.

3.

TLR7 polymorphism, sex and chronic HBV infection influence plasmacytoid DC maturation by TLR7 ligands.

Buschow SI, Biesta PJ, Groothuismink ZMA, Erler NS, Vanwolleghem T, Ho E, Najera I, Ait-Goughoulte M, de Knegt RJ, Boonstra A, Woltman AM.

Antiviral Res. 2018 Sep;157:27-37. doi: 10.1016/j.antiviral.2018.06.015. Epub 2018 Jun 28.

4.

Transcriptional patterns associated with BDCA3 expression on BDCA1+ myeloid dendritic cells.

van der Aa E, Biesta PJ, Woltman AM, Buschow SI.

Immunol Cell Biol. 2018 Mar;96(3):330-336. doi: 10.1111/imcb.12002. Epub 2018 Feb 1.

PMID:
29363156
5.

HBV-Derived Synthetic Long Peptide Can Boost CD4+ and CD8+ T-Cell Responses in Chronic HBV Patients Ex Vivo.

Dou Y, van Montfoort N, van den Bosch A, de Man RA, Zom GG, Krebber WJ, Melief CJM, Buschow SI, Woltman AM.

J Infect Dis. 2018 Feb 14;217(5):827-839. doi: 10.1093/infdis/jix614.

6.

The Effect of Chronic Hepatitis B Virus Infection on BDCA3+ Dendritic Cell Frequency and Function.

van der Aa E, Buschow SI, Biesta PJ, Janssen HL, Woltman AM.

PLoS One. 2016 Aug 16;11(8):e0161235. doi: 10.1371/journal.pone.0161235. eCollection 2016.

7.

Similar frequencies, phenotype and activation status of intrahepatic NK cells in chronic HBV patients after long-term treatment with tenofovir disoproxil fumarate (TDF).

Tjwa ET, Zoutendijk R, van Oord GW, Boeijen LL, Reijnders JG, van Campenhout MJ, de Knegt RJ, Janssen HL, Woltman AM, Boonstra A.

Antiviral Res. 2016 Aug;132:70-5. doi: 10.1016/j.antiviral.2016.05.016. Epub 2016 May 27.

PMID:
27237584
8.

Hepatitis B Virus Surface Antigen Activates Myeloid Dendritic Cells via a Soluble CD14-Dependent Mechanism.

van Montfoort N, van der Aa E, van den Bosch A, Brouwers H, Vanwolleghem T, Janssen HLA, Javanbakht H, Buschow SI, Woltman AM.

J Virol. 2016 Jun 24;90(14):6187-6199. doi: 10.1128/JVI.02903-15. Print 2016 Jul 15.

9.

To target or not to target viral antigens in HBV related HCC?

Buschow SI, Sprengers D, Woltman AM.

J Hepatol. 2015 Jun;62(6):1449-50. doi: 10.1016/j.jhep.2015.01.043. Epub 2015 Feb 21. No abstract available.

10.

BDCA3 expression is associated with high IFN-λ production by CD34(+)-derived dendritic cells generated in the presence of GM-CSF, IL-4, and/or TGF-β.

van der Aa E, van de Laar L, Janssen HL, van Montfoort N, Woltman AM.

Eur J Immunol. 2015 May;45(5):1471-81. doi: 10.1002/eji.201444802. Epub 2015 Feb 14.

11.

Kupffer cells interact with hepatitis B surface antigen in vivo and in vitro, leading to proinflammatory cytokine production and natural killer cell function.

Boltjes A, van Montfoort N, Biesta PJ, Op den Brouw ML, Kwekkeboom J, van der Laan LJ, Janssen HL, Boonstra A, Woltman AM.

J Infect Dis. 2015 Apr 15;211(8):1268-78. doi: 10.1093/infdis/jiu599. Epub 2014 Oct 31.

PMID:
25362194
12.

BDCA3(+)CLEC9A(+) human dendritic cell function and development.

van der Aa E, van Montfoort N, Woltman AM.

Semin Cell Dev Biol. 2015 May;41:39-48. doi: 10.1016/j.semcdb.2014.05.016. Epub 2014 Jun 6. Review.

PMID:
24910448
13.

Monocytes from chronic HBV patients react in vitro to HBsAg and TLR by producing cytokines irrespective of stage of disease.

Boltjes A, Groothuismink ZM, van Oord GW, Janssen HL, Woltman AM, Boonstra A.

PLoS One. 2014 May 13;9(5):e97006. doi: 10.1371/journal.pone.0097006. eCollection 2014.

14.

The role of Kupffer cells in hepatitis B and hepatitis C virus infections.

Boltjes A, Movita D, Boonstra A, Woltman AM.

J Hepatol. 2014 Sep;61(3):660-71. doi: 10.1016/j.jhep.2014.04.026. Epub 2014 May 4. Review.

15.

Understanding MHC class I presentation of viral antigens by human dendritic cells as a basis for rational design of therapeutic vaccines.

van Montfoort N, van der Aa E, Woltman AM.

Front Immunol. 2014 Apr 23;5:182. doi: 10.3389/fimmu.2014.00182. eCollection 2014. Review.

16.

Identification of a novel CD40 ligand for targeted imaging of inflammatory plaques by phage display.

Yu H, Segers F, Sliedregt-Bol K, Bot I, Woltman AM, Boross P, Verbeek S, Overkleeft H, van der Marel GA, van Kooten C, van Berkel TJ, Biessen EA.

FASEB J. 2013 Oct;27(10):4136-46. doi: 10.1096/fj.12-224667. Epub 2013 Jul 29.

PMID:
23896727
17.

Intrahepatic natural killer cell activation, but not function, is associated with HBsAg levels in patients with HBeAg-negative chronic hepatitis B.

Tjwa ET, Zoutendijk R, van Oord GW, Biesta PJ, Verheij J, Janssen HL, Woltman AM, Boonstra A.

Liver Int. 2014 Mar;34(3):396-404. doi: 10.1111/liv.12272. Epub 2013 Jul 25.

PMID:
23890390
18.

PI3K-PKB hyperactivation augments human plasmacytoid dendritic cell development and function.

van de Laar L, van den Bosch A, Boonstra A, Binda RS, Buitenhuis M, Janssen HL, Coffer PJ, Woltman AM.

Blood. 2012 Dec 13;120(25):4982-91. doi: 10.1182/blood-2012-02-413229. Epub 2012 Oct 22.

PMID:
23091295
19.

CD64 distinguishes macrophages from dendritic cells in the gut and reveals the Th1-inducing role of mesenteric lymph node macrophages during colitis.

Tamoutounour S, Henri S, Lelouard H, de Bovis B, de Haar C, van der Woude CJ, Woltman AM, Reyal Y, Bonnet D, Sichien D, Bain CC, Mowat AM, Reis e Sousa C, Poulin LF, Malissen B, Guilliams M.

Eur J Immunol. 2012 Dec;42(12):3150-66. doi: 10.1002/eji.201242847. Epub 2012 Oct 17.

20.

Assessment of the effect of ribavirin on myeloid and plasmacytoid dendritic cells during interferon-based therapy of chronic hepatitis B patients.

Boltjes A, Op den Brouw ML, Biesta PJ, Binda RS, van der Molen RG, Boonstra A, Janssen HL, Woltman AM.

Mol Immunol. 2013 Jan;53(1-2):72-8. doi: 10.1016/j.molimm.2012.06.016. Epub 2012 Jul 20.

PMID:
22814486
21.

Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy.

van de Laar L, Coffer PJ, Woltman AM.

Blood. 2012 Apr 12;119(15):3383-93. doi: 10.1182/blood-2011-11-370130. Epub 2012 Feb 8. Review.

PMID:
22323450
22.

Restoration of TLR3-activated myeloid dendritic cell activity leads to improved natural killer cell function in chronic hepatitis B virus infection.

Tjwa ET, van Oord GW, Biesta PJ, Boonstra A, Janssen HL, Woltman AM.

J Virol. 2012 Apr;86(8):4102-9. doi: 10.1128/JVI.07000-11. Epub 2012 Feb 8.

23.

Hepatitis B virus suppresses the functional interaction between natural killer cells and plasmacytoid dendritic cells.

Shi CC, Tjwa ET, Biesta PJ, Boonstra A, Xie Q, Janssen HL, Woltman AM.

J Viral Hepat. 2012 Feb;19(2):e26-33. doi: 10.1111/j.1365-2893.2011.01496.x. Epub 2011 Aug 31.

PMID:
22239523
24.

Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B.

Sonneveld MJ, Wong VW, Woltman AM, Wong GL, Cakaloglu Y, Zeuzem S, Buster EH, Uitterlinden AG, Hansen BE, Chan HL, Janssen HL.

Gastroenterology. 2012 Mar;142(3):513-520.e1. doi: 10.1053/j.gastro.2011.11.025. Epub 2011 Nov 19.

PMID:
22108195
25.

Tight control of STAT5 activity determines human CD34-derived interstitial dendritic cell and langerhans cell development.

van de Laar L, van den Bosch A, Wierenga AT, Janssen HL, Coffer PJ, Woltman AM.

J Immunol. 2011 Jun 15;186(12):7016-24. doi: 10.4049/jimmunol.1003977. Epub 2011 May 20.

26.

Hepatitis B virus lacks immune activating capacity, but actively inhibits plasmacytoid dendritic cell function.

Woltman AM, Op den Brouw ML, Biesta PJ, Shi CC, Janssen HL.

PLoS One. 2011 Jan 5;6(1):e15324. doi: 10.1371/journal.pone.0015324.

27.

Clinical experience with α-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection.

Schneiders FL, Scheper RJ, von Blomberg BM, Woltman AM, Janssen HL, van den Eertwegh AJ, Verheul HM, de Gruijl TD, van der Vliet HJ.

Clin Immunol. 2011 Aug;140(2):130-41. doi: 10.1016/j.clim.2010.11.010. Epub 2010 Dec 18. Review.

PMID:
21169066
28.

Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B.

Tjwa ET, van Oord GW, Hegmans JP, Janssen HL, Woltman AM.

J Hepatol. 2011 Feb;54(2):209-18. doi: 10.1016/j.jhep.2010.07.009. Epub 2010 Sep 6.

PMID:
21095036
29.

A nonredundant role for canonical NF-κB in human myeloid dendritic cell development and function.

van de Laar L, van den Bosch A, van der Kooij SW, Janssen HL, Coffer PJ, van Kooten C, Woltman AM.

J Immunol. 2010 Dec 15;185(12):7252-61. doi: 10.4049/jimmunol.1000672. Epub 2010 Nov 12.

30.

Human CD34-derived myeloid dendritic cell development requires intact phosphatidylinositol 3-kinase-protein kinase B-mammalian target of rapamycin signaling.

van de Laar L, Buitenhuis M, Wensveen FM, Janssen HL, Coffer PJ, Woltman AM.

J Immunol. 2010 Jun 15;184(12):6600-11. doi: 10.4049/jimmunol.0903089. Epub 2010 May 19.

31.

Dendritic cells in chronic viral hepatitis B and C: victims or guardian angels?

Woltman AM, Boonstra A, Janssen HL.

Gut. 2010 Jan;59(1):115-25. doi: 10.1136/gut.2009.181040. Review. No abstract available.

PMID:
20007959
32.

Alpha-galactosylceramide in chronic hepatitis B infection: results from a randomized placebo-controlled Phase I/II trial.

Woltman AM, Ter Borg MJ, Binda RS, Sprengers D, von Blomberg BM, Scheper RJ, Hayashi K, Nishi N, Boonstra A, van der Molen R, Janssen HL.

Antivir Ther. 2009;14(6):809-18. doi: 10.3851/IMP1295.

PMID:
19812443
33.

The mannose receptor acts as hepatitis B virus surface antigen receptor mediating interaction with intrahepatic dendritic cells.

Op den Brouw ML, Binda RS, Geijtenbeek TB, Janssen HL, Woltman AM.

Virology. 2009 Oct 10;393(1):84-90. doi: 10.1016/j.virol.2009.07.015. Epub 2009 Aug 15.

34.

Immunology of hepatitis B and hepatitis C virus infections.

Boonstra A, Woltman AM, Janssen HL.

Best Pract Res Clin Gastroenterol. 2008;22(6):1049-61. doi: 10.1016/j.bpg.2008.11.015. Review.

PMID:
19187866
35.

Handbook of experimental pharmacology "dendritic cells": the use of dexamethasone in the induction of tolerogenic DCs.

van Kooten C, Stax AS, Woltman AM, Gelderman KA.

Handb Exp Pharmacol. 2009;(188):233-49. doi: 10.1007/978-3-540-71029-5_11. Review.

PMID:
19031029
36.

Induction of donor-specific T-cell hyporesponsiveness using dexamethasone-treated dendritic cells in two fully mismatched rat kidney transplantation models.

Stax AM, Gelderman KA, Schlagwein N, Essers MC, Kamerling SW, Woltman AM, van Kooten C.

Transplantation. 2008 Nov 15;86(9):1275-82. doi: 10.1097/TP.0b013e31818a6682.

PMID:
19005410
37.

Intrahepatic regulatory T cells are phenotypically distinct from their peripheral counterparts in chronic HBV patients.

Stoop JN, Claassen MA, Woltman AM, Binda RS, Kuipers EJ, Janssen HL, van der Molen RG, Boonstra A.

Clin Immunol. 2008 Dec;129(3):419-27. doi: 10.1016/j.clim.2008.07.029. Epub 2008 Sep 26.

PMID:
18823821
38.

Modulation of dendritic cell function by persistent viruses.

Liu B, Woltman AM, Janssen HL, Boonstra A.

J Leukoc Biol. 2009 Feb;85(2):205-14. doi: 10.1189/jlb.0408241. Epub 2008 Sep 25. Review.

PMID:
18818373
39.

Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus.

Op den Brouw ML, Binda RS, van Roosmalen MH, Protzer U, Janssen HL, van der Molen RG, Woltman AM.

Immunology. 2009 Feb;126(2):280-9. doi: 10.1111/j.1365-2567.2008.02896.x. Epub 2008 Jun 28.

40.

Branched oligosaccharide structures on HBV prevent interaction with both DC-SIGN and L-SIGN.

Op den Brouw ML, de Jong MA, Ludwig IS, van der Molen RG, Janssen HL, Geijtenbeek TB, Woltman AM.

J Viral Hepat. 2008 Sep;15(9):675-83. doi: 10.1111/j.1365-2893.2008.00993.x. Epub 2008 May 14.

PMID:
18482282
41.

CD40L stimulation of rat dendritic cells specifically favors the IL-12/IL-10 ratio resulting in a strong T cell stimulatory capacity.

Stax AM, Crul C, Kamerling SW, Schlagwein N, van der Geest RN, Woltman AM, van Kooten C.

Mol Immunol. 2008 May;45(9):2641-50. doi: 10.1016/j.molimm.2007.12.014. Epub 2008 Feb 8.

PMID:
18262271
42.

Immune modulation of human dendritic cells by complement.

Castellano G, Woltman AM, Schlagwein N, Xu W, Schena FP, Daha MR, van Kooten C.

Eur J Immunol. 2007 Oct;37(10):2803-11.

43.

Tumor necrosis factor alpha inhibits the suppressive effect of regulatory T cells on the hepatitis B virus-specific immune response.

Stoop JN, Woltman AM, Biesta PJ, Kusters JG, Kuipers EJ, Janssen HL, van der Molen RG.

Hepatology. 2007 Sep;46(3):699-705.

PMID:
17654744
44.

Quantification of dendritic cell subsets in human renal tissue under normal and pathological conditions.

Woltman AM, de Fijter JW, Zuidwijk K, Vlug AG, Bajema IM, van der Kooij SW, van Ham V, van Kooten C.

Kidney Int. 2007 May;71(10):1001-8. Epub 2007 Mar 14.

45.

Maturation-resistant dendritic cells induce hyporesponsiveness in alloreactive CD45RA+ and CD45RO+ T-cell populations.

Woltman AM, van der Kooij SW, de Fijter JW, van Kooten C.

Am J Transplant. 2006 Nov;6(11):2580-91. Epub 2006 Sep 4.

46.

IL-10-producing macrophages preferentially clear early apoptotic cells.

Xu W, Roos A, Schlagwein N, Woltman AM, Daha MR, van Kooten C.

Blood. 2006 Jun 15;107(12):4930-7. Epub 2006 Feb 23.

PMID:
16497970
47.

Renal tubular epithelial cells modulate T-cell responses via ICOS-L and B7-H1.

de Haij S, Woltman AM, Trouw LA, Bakker AC, Kamerling SW, van der Kooij SW, Chen L, Kroczek RA, Daha MR, van Kooten C.

Kidney Int. 2005 Nov;68(5):2091-102.

48.

Dendritic cells of IgA nephropathy patients have an impaired capacity to induce IgA production in naïve B cells.

Eijgenraam JW, Woltman AM, Kamerling SW, Briere F, de Fijter JW, Daha MR, van Kooten C.

Kidney Int. 2005 Oct;68(4):1604-12.

49.

MIP-3alpha/CCL20 in renal transplantation and its possible involvement as dendritic cell chemoattractant in allograft rejection.

Woltman AM, de Fijter JW, van der Kooij SW, Jie KE, Massacrier C, Caux C, Daha MR, van Kooten C.

Am J Transplant. 2005 Sep;5(9):2114-25.

50.

Opsonization with C1q and mannose-binding lectin targets apoptotic cells to dendritic cells.

Nauta AJ, Castellano G, Xu W, Woltman AM, Borrias MC, Daha MR, van Kooten C, Roos A.

J Immunol. 2004 Sep 1;173(5):3044-50.

Supplemental Content

Support Center